BioWorld Asia

Sep. 17, 2008

View Archived Issues

Blocking Heat Shock Proteins Points to More Selective Drugs

Unibioscreen Gets Up to $31M in Cancer Drug Deal with Drais

NicOx Shows Positive Data From 2nd Naproxcinod Trial

Polyplus-transfection Develops New Class of Oligonucleotides

Biomarker Data Point to Target Patients for Transgene's Vaccine

CV Therapeutics Gets $70M Up Front in Ex-U.S. Ranexa Deal

Other News To Note

Cell Medica Begins Study of CMV Transplant Therapy

LONDON - Cell Medica Ltd. has treated the first patient in a Phase III trial of a cell therapy treatment for the prevention of cytomegalovirus (CMV) infection in immunocompromised bone marrow transplant patients. (BioWorld International) Read More

HemoCORM, Alfama Align in Carbon Monoxide Deal

Today's news in brief

BioWorld

BioWorld briefs for April 2, 2026.

With improved technologies, biomarkers, failed drugs may come into their own

BioWorld

At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...

Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

Small-molecule TREM2 agonist advances to treat Alzheimer’s

BioWorld Science

Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...

Amlogenyx’s AM-805 reduces amyloid plaques in AD

BioWorld Science

The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 31, 2026